Skip to main content
SpringerLink
Log in

Motor neuron disease

Urgently needed—biomarkers for amyotrophic lateral sclerosis

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

The development of disease-modifying therapies for amyotrophic lateral sclerosis (ALS) is a priority for researchers in this field. Two studies have independently identified plasma and cerebrospinal fluid biomarkers for ALS, and these biomarkers could provide a means of testing the efficacy of novel ALS drug treatments in future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Turner, M. R., Kiernan, M. C., Leigh, P. N. & Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 8, 94–109 (2009).

    Article  CAS  Google Scholar 

  2. Mitchell, R. M., Simmons, Z., Beard, J. L., Stephens, H. E. & Connor, J. R. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 42, 95–103 (2010).

    Article  CAS  Google Scholar 

  3. Ryberg, H. et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42, 104–111 (2010).

    Article  CAS  Google Scholar 

  4. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389–1392 (2006).

    Article  CAS  Google Scholar 

  5. Brettschneider, J., Petzold, A., Sussmuth, S. D., Ludolph, A. & Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 28, 852–856 (2006).

    Article  Google Scholar 

  6. Süssmuth, S. D. et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74, 982–987 (2010).

    Article  Google Scholar 

  7. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).

    Article  CAS  Google Scholar 

  8. Steinacker, P. et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 65, 1481–1487 (2008).

    Article  Google Scholar 

  9. Braak, H., Ludolph, A. C., Thal, D. R & Del Tredici, K. Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 120, 67–74 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Ulm, 89075 Ulm, 45, Oberer Eselsberg, Germany

    Albert C. Ludolph

Authors
  1. Albert C. Ludolph
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludolph, A. Urgently needed—biomarkers for amyotrophic lateral sclerosis. Nat Rev Neurol 7, 13–14 (2011). https://doi.org/10.1038/nrneurol.2010.196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.196

  • Springer Nature Limited

This article is cited by

Search

Navigation